President Trump’s April 2, 2026, Proclamation under Section 232 of the Trade Expansion Act of 1962 establishes a 100 percent ad valorem tariff on patented pharmaceutical products and their associated active pharmaceutical ingredients (APIs) imported into the United States. For pharmaceutical companies — and for the institutional investors, suppliers, and licensors connected to them — the tariff is not a proposed rule subject to comment. It is signed policy with three compliance pathways, hard effective dates beginning July 31, 2026, and retroactive penalty provisions for companies that commit to onshoring and fail to deliver.
This is a board-level decision item, not a regulatory monitoring matter. The question before every pharmaceutical company board is which of the three available pathways it will commit to, and that decision carries consequences that range from margin compression of 20 to 100 percentage points on affected product lines to binding pricing agreements with the Department of Health and Human Services. Neither choice is cost-free. Neither can be deferred past the deadline without surrendering the most favorable option. The Commerce Department criteria for qualifying onshoring plans have not yet been published in the Federal Register, and boards that wait for those criteria before acting will have compressed the time available to prepare a credible submission.
What the Proclamation Actually Does
The April 2 Proclamation establishes a tiered tariff structure applied to pharmaceutical products listed in the FDA’s Orange Book for patented drugs or the Purple Book for licensed biological products, and to their associated APIs and key raw materials. The baseline rate is 100 percent ad valorem. The Proclamation also establishes a 15 percent rate for covered products originating from strategic partner countries: the European Union, Japan, South Korea, Switzerland, and Liechtenstein.
The scope of the exposure is material for any company that sources patented product or APIs internationally. As of 2025, approximately 53 percent of patented pharmaceuticals distributed in the United States were produced abroad, and 85 percent of patented APIs were sourced from foreign manufacturers. The Proclamation applies product-by-product and company-by-company, which means boards cannot rely on aggregate supply chain estimates. A patent-level inventory of sourcing for every drug on a company’s portfolio is a prerequisite to any compliance strategy.
Generics are excluded from the tariff at this time, as are orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell and gene therapies. For diversified pharmaceutical companies with both branded and generic portfolios, the exclusion of generics does not reduce the exposure on the patented side of the business. It means the tariff creates a structural cost asymmetry within a single company’s portfolio that boards must account for in their pathway analysis.
The Three Pathways
The Proclamation establishes three distinct compliance pathways, each with different cost, commitment, and timeline implications.
The first pathway is absorption: accept the 100 percent tariff as a cost of doing business and pass it through to pricing, absorb it in margin, or renegotiate supply contracts to shift incidence. For companies with limited foreign-sourced patented product exposure, this pathway may be operationally manageable. For companies with significant international API sourcing, the margin compression is existential on affected product lines. The 100 percent rate is not a negotiating position. It is the default outcome for any company that takes no action.
The second pathway is onshoring commitment: submit a qualifying onshoring plan to the Commerce Department and receive a reduced tariff rate of 20 percent during the commitment period. The criteria for a qualifying onshoring plan have not yet been published in the Federal Register. The Commerce Department is expected to publish those criteria after the Proclamation’s effective date. Companies that submit qualifying plans will receive the 20 percent rate retroactively to the date of their submission, which creates a strong incentive to submit early even before criteria are finalized, provided the commitment is genuine and documentable.
The third pathway is the combination of onshoring commitment and Most Favored Nation pricing agreement: companies that commit to onshoring and agree to align U.S. prices for covered products with the lowest prices charged to comparable foreign markets receive a 0 percent tariff rate through December 31, 2029. This is the most favorable rate available, and it is also the most structurally demanding. It requires both a credible onshoring commitment and a pricing concession that, for branded products with significant U.S.-international price differentials, represents a material revenue reduction.
The Annex III Companies and the 100-Day Clock
The Proclamation identifies 17 companies by name in Annex III as having the highest concentration of foreign-sourced patented pharmaceutical exposure. For these companies, the 100 percent default tariff rate takes effect on July 31, 2026 — 100 days from the April 2 signing date. All other covered companies face the same default rate on September 29, 2026, unless they have submitted and received approval for a qualifying onshoring plan.
For Annex III companies, 100 days is sufficient time to make a well-analyzed decision. It is not sufficient time to wait for events to clarify before beginning the analysis. The Commerce Department criteria for onshoring plans will be published after the effective date, but the internal work required to prepare a credible submission — patent-level sourcing inventory, financial modeling of pathway options, contract review, board authorization — will require weeks of preparation before any submission is made. Boards of Annex III companies that have not yet initiated this work are operating on a compressed and potentially unworkable timeline.
Contract and Licensing Implications
The tariff incidence question — who bears the economic cost of the tariff — is not automatically resolved by the Proclamation. It is determined by the contracts in place between pharmaceutical companies and their manufacturing partners, licensors, co-commercialization partners, and distributors. Many pharmaceutical agreements were drafted without anticipation of a 100 percent import tariff, and the allocation of tariff costs under those agreements may not fall where management assumes it does.
Licensing agreements that include royalty provisions based on net sales, collaboration agreements with cost-sharing provisions, and contract manufacturing agreements with fixed-price or cost-plus structures all contain language that will be read differently in a 100 percent tariff environment than it was when the agreements were executed. Boards should direct management to conduct a systematic review of all material agreements that include pricing, cost allocation, or supply chain provisions, with specific attention to whether tariff costs are borne by the company, passed to the counterparty, or shared in a ratio that was not intended to apply to a tariff of this magnitude.
The retroactive penalty provisions for companies that commit to onshoring and fail to deliver add a second layer of contractual complexity. A board that approves an onshoring commitment is authorizing a binding obligation with financial consequences for non-performance. The commitment must be genuine, documented, and achievable, because misrepresentation is not treated as a compliance failure — it is treated as a legal liability with retroactive financial consequences.
The Strategic Implication of the MFN Trade
The zero-tariff pathway creates a direct tension between supply chain cost and pricing strategy. MFN pharmaceutical pricing agreements require companies to align U.S. prices for covered products with the lowest prices charged to comparable foreign markets. For branded products with significant price differentials between the U.S. and international markets, this is not a footnote concession. It is a structural revenue reduction. Boards must examine each product for which the MFN pathway is being considered and determine whether the tariff savings exceed the pricing reduction required to qualify. The answer will differ by drug, by market, and by patent life remaining.
Several large pharmaceutical companies have already made public onshoring investment commitments, contributing to the approximately $400 billion in announced investment that the administration cited in the White House fact sheet accompanying the Proclamation. These announcements function partly as diplomatic positioning, partly as attempts to favorably influence the criteria the Commerce Department will publish. Boards that have not yet made public commitments are operating in an information environment where competitors’ stated intentions may affect how the compliance criteria are written and enforced.
The Governance Imperative
A 100 percent tariff on imports constituting more than half of a company’s patented drug supply is a material financial event. Boards have an obligation to quantify the exposure and assess it against the compliance pathways available before the July 31 effective date arrives. Three categories of internal review are required immediately. First, a patent-level inventory of all affected products and their sourcing, covering both finished drug product and API. Second, a contract review of all licensing, collaboration, co-commercialization, and contract manufacturing agreements that include pricing provisions or allocation of import costs, because tariff incidence under those agreements may not fall where management assumes it does. Third, a disclosure assessment, because material changes in supply chain cost and pricing strategy are subject to securities disclosure obligations and proxy-season investor scrutiny.
Boards whose management teams have not yet delivered a formal tariff exposure quantification with pathway analysis are behind the decision timeline. The Commerce Department criteria for onshoring plans will be published in the Federal Register after the Proclamation’s effective date, but the evaluation, board decision, and submission preparation will require weeks of internal work before any submission is made. Boards that treat the publication of Commerce criteria as the starting point rather than as a confirmation step are working from an unworkable timeline.
Available Pathways and the Urgency of Action
The three pathways available — absorb the 100 percent tariff, commit to onshoring for a 20 percent rate, or combine onshoring with MFN pricing for a 0 percent rate through 2029 — are structurally different strategic choices, not simply administrative filings. Each pathway commits a company to a position on pricing, capital allocation, and supply chain architecture that will define its competitive standing for the remainder of the decade. The window to enter the most favorable pathway has a defined outer boundary at September 29, 2026, for most companies and July 31 for the 17 named in Annex III. For companies in the Annex III group, 100 days remain. That is sufficient time to make a well-analyzed decision. It is not sufficient time to wait for events to clarify before beginning the analysis.